Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial

[Figure: see text]

Detalles Bibliográficos
Autores principales: Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A. M. A., Fayed, Mona M. H. E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J., Snel, Alexander N., Bachas, Costa, Tettero, Jesse M., Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjørn T., Griškevičius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A., Maertens, Johan A., Manz, Markus G., Pabst, Thomas, Passweg, Jakob R., Porkka, Kimmo, Valk, Peter J. M., Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C., Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., Cloos, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646801/
https://www.ncbi.nlm.nih.gov/pubmed/36898087
http://dx.doi.org/10.1182/blood.2022019160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646801/
https://www.ncbi.nlm.nih.gov/pubmed/36898087
http://dx.doi.org/10.1182/blood.2022019160

Ejemplares similares